Results 81 to 90 of about 7,902 (191)

Impact of Prior Angiotensin‐Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use on Delirium Incidence in ICU Patients: A Retrospective Study

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims This investigation aimed at exploring the impact that the pre‐existing use of angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) has on the incidence of delirium in patients within the intensive care unit (ICU).
Zhe Li   +4 more
wiley   +1 more source

Vascular Calcification: Mechanisms, Models, and Therapies

open access: yesiNew Medicine, Volume 2, Issue 2, June 2026.
ABSTRACT Vascular calcification represents an active multifactorial process that mirrors several key features of skeletal bone mineralization. Clinically, it is characterized by diminished arterial compliance and increased arterial wall stiffness, both of which serve as independent predictors of significant adverse cardiovascular events.
Wenya Zhu   +5 more
wiley   +1 more source

Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies.

open access: yes, 2013
What is known and Objective: To evaluate the effects of an olmesartan/amlodipine single pill combination compared with olmesartan or amlodipine monotherapies on blood pressure control, lipid profile, insulin sensitivity and some adipocytokines levels ...
CICERO, ARRIGO FRANCESCO GIUSEPPE   +6 more
core   +1 more source

CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION

open access: yesКлиническая практика, 2016
The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the ...
A G Evdokimova   +2 more
doaj   +1 more source

Olmesartan‐induced enteropathy

open access: yes, 2015
Olmesartan‐induced ...
S Wallace (13279542)   +2 more
core  

Hypertension: Focus on Olmesartan Medoxomil

open access: yes, 2009
Hypertension is the leading cause of stroke, heart failure, and ischemic heart disease. One of the key regulators of blood pressure is the renin-angiotensin aldosterone system (RAAS).
Allison M. Bell, Diane Nykamp
core   +1 more source

LC-MS method for determination of olmesartan in human plasma

open access: yes, 2015
Olmesartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily and is used to treat high blood pressure (hypertension).
Edyta Piórkowska   +4 more
core   +1 more source

Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies.

open access: yes, 2013
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy.
Maffioli P.   +6 more
core   +1 more source

Comparative Study of olmesartan and losartan in patient with hypertension for reduction of diastolic blood pressure on male patient more than 55 years [PDF]

open access: yes, 2021
Antihypertensive drugs are used to reduce blood pressure. Angiotensin receptor blocker shows beneficial effect to control target organ damage. Study was carried out for production of hypertension by psychogenic stress method.In present work done by me ...
Kumari, Asha, Jha, Amit Kumar
core  

Olmesartan (Benicar) for hypertension

open access: yes, 2005
Olmesartan (Benicar) is an angiotensin-II receptor blocker (ARB) labeled for the treatment of hypertension as monotherapy or in combination with other antihypertensive agents.
Ward, Kristina E., Hume, L.
core   +1 more source

Home - About - Disclaimer - Privacy